A phase II trial of dostarlimab and niraparib combination therapy in patients with stage III-IV recurrent or refractory penile cancer. Association of baseline and on-treatment ctDNA fraction with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback